Spots Global Cancer Trial Database for colorectal cancer recurrent
Every month we try and update this database with for colorectal cancer recurrent cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Predicting Local and Distant Recurrence in T1 Colorectal Cancer | NCT06314971 | Colorectal Canc... Colorectal Neop... Colorectal Aden... Colorectal Canc... Colorectal Neop... Colorectal Canc... | Tw1CE | 18 Years - | City of Hope Medical Center | |
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer | NCT04067986 | Colorectal Canc... | Camrelizumab Apatinib | 18 Years - 75 Years | Zhongshan Hospital Xiamen University | |
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations | NCT06229340 | RAS Mutation Ras (Kras or Nr... Colorectal Canc... Pancreas Cancer Lung Cancer Melanoma Refractory Canc... | Leflunomide The combination... | 18 Years - 85 Years | N.N. Petrov National Medical Research Center of Oncology | |
Early-Onset Colorectal Cancer Recurrence | NCT06271980 | Colorectal Canc... Colorectal Canc... Colorectal Neop... Colorectal Aden... Colorectal Canc... Colorectal Canc... Colorectal Canc... | ENCORE | 18 Years - 50 Years | City of Hope Medical Center | |
Predicting Local and Distant Recurrence in T1 Colorectal Cancer | NCT06314971 | Colorectal Canc... Colorectal Neop... Colorectal Aden... Colorectal Canc... Colorectal Neop... Colorectal Canc... | Tw1CE | 18 Years - | City of Hope Medical Center | |
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations | NCT06229340 | RAS Mutation Ras (Kras or Nr... Colorectal Canc... Pancreas Cancer Lung Cancer Melanoma Refractory Canc... | Leflunomide The combination... | 18 Years - 85 Years | N.N. Petrov National Medical Research Center of Oncology | |
A Study of Famitinib in Patients With Advanced Colorectal Cancer | NCT01762293 | Colorectal Canc... Colorectal Canc... Colorectal Canc... | Famitinib placebo | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations | NCT06229340 | RAS Mutation Ras (Kras or Nr... Colorectal Canc... Pancreas Cancer Lung Cancer Melanoma Refractory Canc... | Leflunomide The combination... | 18 Years - 85 Years | N.N. Petrov National Medical Research Center of Oncology | |
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT) | NCT02390947 | Colorectal Canc... Colorectal Canc... | Famitinib Placebo | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer | NCT04067986 | Colorectal Canc... | Camrelizumab Apatinib | 18 Years - 75 Years | Zhongshan Hospital Xiamen University | |
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients | NCT04368507 | Colorectal Canc... Colorectal Canc... | YYB101 | 19 Years - | CellabMED | |
Early-Onset Colorectal Cancer Recurrence | NCT06271980 | Colorectal Canc... Colorectal Canc... Colorectal Neop... Colorectal Aden... Colorectal Canc... Colorectal Canc... Colorectal Canc... | ENCORE | 18 Years - 50 Years | City of Hope Medical Center | |
Stage II/III Colorectal Cancer Recurrence | NCT06314958 | Colorectal Canc... Colorectal Aden... Colorectal Canc... Colorectal Canc... Colorectal Canc... | CENSURE | 18 Years - | City of Hope Medical Center |